Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

FDA approves Tepezza for the treatment of thyroid eye in adults

2
SHARES

The US FDA approved Tepezza (teprotumumab-trbw), the first treatment for thyroid eye, on the basis of two trials in which the drug improved eye protrusion in patients.

FDA approved stamp with pills

The US Food and Drug Administration (FDA) has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

“Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non‑surgical treatment option,” said Dr Wiley Chambers, deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research.

Thyroid eye is a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis).

image of a patient with proptosis, or bulging eye

Patient with proptosis.

The approval, granted to Horizon Therapeutics Ireland DAC, was based on the results of two studies, totalling 170 patients with active thyroid eye disease which were randomised into two groups: placebo or Tepezza. Of those administered Tepezza 71 percent in study one and 83 percent in study two demonstrated a greater than 2mm reduction in proptosis, where the placebo had 20 percent and 10 percent, respectively.

The adverse reactions included muscle spasm, nausea, alopecia, fatigue, hearing loss, headache and hyperglycemia, among others.

The FDA also granted the drug Priority Review, Fast Track designation, Breakthrough Therapy designation and Orphan Drug Designation.

Share via
Share via